ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2022
Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Variable selection for prediction models of Omicron infection: Insights from two population-based cohort studies.Diagnostic and prognostic research · 2026Article
- Article
- (Fear of) SARS-CoV-2 infection and psychological distress: a population-based cohort study in southern Switzerland.Epidemiology and psychiatric sciences · 2024Article
- Sexual behaviours and risk of SARS-CoV-2 infection among MSM during the first COVID-19 lockdown.BMC public health · 2024Article
- Development of hybrid immunity during a period of high incidence of Omicron infections.International journal of epidemiology · 2023Article
- Persistent humoral immune response in youth throughout the COVID-19 pandemic: prospective school-based cohort study.Nature communications · 2023Article
- Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection.Nature communications · 2023Article
- Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study.International journal of environmental research and public health · 2023Article
- Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave.International journal of environmental research and public health · 2023Article
- Article
- The Detection of Periodic Reemergence Events of SARS-CoV-2 Delta Strain in Communities Dominated by Omicron.Pathogens (Basel, Switzerland) · 2022Article
- Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses.Microbiology spectrum · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional immunity (defined here as serum neutralising capacity) critically contributes to conferring protection against SARS-CoV-2 infection and severe COVID-19. This cross-sectional analysis of a prospective, population-based cohort study included 1,894 randomly-selected 16 to 99-year-old participants from two Swiss cantons in March 2022. Of these, 97.6% (95% CI: 96.8-98.2%) had anti-spike IgG antibodies, and neutralising capacity was respectively observed for 94%, 92% and 88% against wild-type SARS-CoV-2, Delta and Omicron variants. Studying functional immunity to inform and monitor vaccination campaigns is crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.